News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Taking lenient stance, NICE backs neuroblastoma drug Body makes special case due to rarity of the disease
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
